The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.
Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.
Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.
Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.
The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.
The purpose of this study is to assess the physical activity practices of college-age Native American adults.
Are you suspected of having or have been diagnosed with ovarian cancer? if so, you may be able to participate in a research study looking at creating personalized stem cells from the skin of ovarian cancer patients to see if these stem cells can attack cancer cells. This work may be able to help us find more treatment options for ovarian cancer patients in the future.
Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.
The purpose of this study is to find out if an investigational medication (NBTXR3) could help elderly patients with locally advanced head & neck squamous cell carcinoma who are otherwise ineligible to receive platinum-based chemotherapy. This study will help to determine the recommended dose/s of NBTXR3. The study medication is injected directly into the tumor and is activated by radiation therapy in combination with anti-PD1 therapy.
Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.